(0.14%) 5 315.70 points
(0.20%) 39 989 points
(0.10%) 16 759 points
(0.83%) $79.28
(3.44%) $2.50
(-0.43%) $2 384.60
(0.61%) $29.91
(-0.33%) $1 066.60
(0.13%) $0.920
(0.30%) $10.70
(0.07%) $0.789
(0.16%) $90.83
Quarter results today
(bmo 2024-05-16)
Expected move: +/- 7.57%
@ $1.778
Issued: 14 Feb 2024 @ 09:30
Return: 7.97%
Previous signal: Feb 12 - 14:27
Previous signal:
Return: -3.36 %
Live Chart Being Loaded With Signals
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders...
Stats | |
---|---|
Today's Volume | 593 574 |
Average Volume | 1.58M |
Market Cap | 321.43M |
EPS | $0 ( 2024-05-09 ) |
Next earnings date | ( $-0.180 ) 2024-08-06 |
Last Dividend | $6.00 ( 2018-08-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.68 |
ATR14 | $0.00400 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Apeiron Investment Group Ltd. | Buy | 147 950 | Convertible Notes |
2024-04-15 | Apeiron Investment Group Ltd. | Sell | 147 950 | Convertible Notes |
2024-04-02 | Johnson Anne Nagengast | Sell | 27 410 | Common Shares |
2024-04-02 | Rao Srinivas | Sell | 61 640 | Common Shares |
2024-04-02 | Kirpekar Sahil | Sell | 35 801 | Common Shares |
INSIDER POWER |
---|
56.56 |
Last 90 transactions |
Buy: 18 737 833 | Sell: 13 770 797 |
Volume Correlation
ATA Inc. Correlation
10 Most Positive Correlations | |
---|---|
LLNW | 0.94 |
PAVM | 0.928 |
SVOK | 0.916 |
IMCC | 0.913 |
NVTSW | 0.913 |
SWAV | 0.912 |
QTEK | 0.912 |
RDHL | 0.911 |
QAT | 0.91 |
NKTX | 0.91 |
10 Most Negative Correlations | |
---|---|
ITMR | -0.949 |
AVEO | -0.939 |
GAINM | -0.933 |
XOMAO | -0.931 |
DVCR | -0.925 |
ALXN | -0.923 |
PPD | -0.923 |
GLLI | -0.923 |
MLCO | -0.923 |
ACAB | -0.922 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
ATA Inc. Correlation - Currency/Commodity
ATA Inc. Financials
Annual | 2023 |
Revenue: | $314 000 |
Gross Profit: | $-5 000.00 (-1.59 %) |
EPS: | $-0.250 |
FY | 2023 |
Revenue: | $314 000 |
Gross Profit: | $-5 000.00 (-1.59 %) |
EPS: | $-0.250 |
FY | 2022 |
Revenue: | $233 000 |
Gross Profit: | $65 000.00 (27.90 %) |
EPS: | $-0.910 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.100 |
Financial Reports:
No articles found.
ATA Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.430 | 2011-06-28 |
Last Dividend | $6.00 | 2018-08-27 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $7.36 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.25 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
OXLC | Dividend Diamond | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend Royal | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -122.03 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.126 | 1.200 | -4.19 | -5.02 | [0 - 0.3] |
returnOnEquityTTM | -0.143 | 1.500 | -2.70 | -4.05 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.83 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.625 | 0.800 | 5.15 | 4.12 | [0.8 - 2.5] |
cashRatioTTM | 1.257 | 1.500 | 4.13 | 6.19 | [0.2 - 2] |
debtRatioTTM | 0.0739 | -1.500 | 8.77 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -86.31 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.533 | 2.00 | -0.178 | -0.355 | [0 - 30] |
freeCashFlowPerShareTTM | -0.534 | 2.00 | -0.267 | -0.534 | [0 - 20] |
debtEquityRatioTTM | 0.0894 | -1.500 | 9.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -0.336 | 1.000 | -8.93 | -8.93 | [0.2 - 0.8] |
operatingProfitMarginTTM | -420.01 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.26 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00103 | 0.800 | -3.33 | -2.66 | [0.5 - 2] |
Total Score | -2.42 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -9.64 | 1.000 | -1.074 | 0 | [1 - 100] |
returnOnEquityTTM | -0.143 | 2.50 | -1.737 | -4.05 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.534 | 2.00 | -0.178 | -0.534 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.533 | 2.00 | -0.178 | -0.355 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.101 | 1.500 | -4.01 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -305.84 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.21 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
ATA Inc.
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators